Grant: Banting Postdoctoral Fellowship Program
Direct Payment
$140,000.00
A high throughput system for delivering genome sequence-based personalized medicine
FY 2010-11
Summary
Cancer is the leading cause of death in the human population. It is estimated that 173,800 individuals will be diagnosed with this disease in Canada in 2010 alone, with 76,000 individuals dying from it. In this current era of cancer genomics, the ability to sequence an individual patient's tumor genome, at a reasonable cost, to identify key cancer causing mutations is becoming closer to a reality. While this should eventually allow for the rational selection of therapeutic options based on an individual patient's genome sequence, the benefit of using such an approach is limited to the small repertoire of targeted therapeutics. One way to expand this repertoire is to include both known and novel compounds that target the products of the genes mutated in the individual's profile. However, the therapeutic would need to be tested in a representative model prior to being considered. While there are approaches to mimic human tumors in model systems, the model may not carry all of the representative changes. Moreover, the amount of time it takes to create the model and test the therapy is long and if the cancer is aggressive, it would not be practical. Hence, having a system that could rapidly create a model that genetically mimics a human tumor would be extremely useful. To this end, I propose to develop a system which would allow for the rapid and high throughput introduction of sequence mutations in human DNA using novel genome engineering approaches. First, I will test my new system by introducing mutations in genes with known functional consequences. Subsequently, I will apply this system to understand the role of combinations of genetic changes in the susceptibility of tobacco-induced lung cancer as well as chemotherapy response. The significance of this work is that this system could be used to make any genetic background on-demand and would represent a major step in genome engineering and substantial progress towards the goal of personalized medicine.
Department
Program
Banting Postdoctoral Fellowship Program
Recipient
Location
Massachusetts, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
218885
Name
Chari Rajagopal
Region
Massachusetts
Country
United States of America
Orgtype
Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
Banting Postdoctoral Fellowships Program
Projecttitle
A high throughput system for delivering genome sequence-based personalized medicine
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Banting Postdoctoral Fellowship Program
Keyworddelim
Cancer; High Throughput Genomics; Susceptibility; Synthetic Biology
Abstract
Cancer is the leading cause of death in the human population. It is estimated that 173,800 individuals will be diagnosed with this disease in Canada in 2010 alone, with 76,000 individuals dying from it. In this current era of cancer genomics, the ability to sequence an individual patient's tumor genome, at a reasonable cost, to identify key cancer causing mutations is becoming closer to a reality. While this should eventually allow for the rational selection of therapeutic options based on an individual patient's genome sequence, the benefit of using such an approach is limited to the small repertoire of targeted therapeutics. One way to expand this repertoire is to include both known and novel compounds that target the products of the genes mutated in the individual's profile. However, the therapeutic would need to be tested in a representative model prior to being considered. While there are approaches to mimic human tumors in model systems, the model may not carry all of the representative changes. Moreover, the amount of time it takes to create the model and test the therapy is long and if the cancer is aggressive, it would not be practical. Hence, having a system that could rapidly create a model that genetically mimics a human tumor would be extremely useful. To this end, I propose to develop a system which would allow for the rapid and high throughput introduction of sequence mutations in human DNA using novel genome engineering approaches. First, I will test my new system by introducing mutations in genes with known functional consequences. Subsequently, I will apply this system to understand the role of combinations of genetic changes in the susceptibility of tobacco-induced lung cancer as well as chemotherapy response. The significance of this work is that this system could be used to make any genetic background on-demand and would represent a major step in genome engineering and substantial progress towards the goal of personalized medicine.
Competitiondate
201011
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Chari, Rajagopal
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~